~~<i id='6922580C43'><strike id='6922580C43'><tt id='6922580C43'><pre id='6922580C43'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：entertainment 2025-09-14 10:07:43 - browse：4641

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Do digital therapeutics have a future in medicine?

entertainment

hotspot

entertainment

explore

focus

leisure time

AdobeTheFoodandDrugAdministrationshouldmovemorequicklytoensurepulseoximeters—theubiquitousdevicesuse

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

Biden administration opens offers in Medicare drug price negotiations

Venture capital firm's plans to take over Akron hospital face hurdles

Why Medicare shouldn’t cover every FDA

Do digital therapeutics have a future in medicine?

Health Care Service Corp to buy Cigna Medicare Advantage plans

focus

entertainment

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Philips to halt sales of sleep apnea machines in U.S.

Walensky prepares to leave CDC — and Congress — behind

Wegovy leads to weight loss. Can it treat depression, too?

Wildfire smoke exposes gaps in outdoor worker protections

Even great ERs can’t make up for American health disparities

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Affordable Care Act has saved billions in health care costs

In Memoriam: Notable people who died in 2023

General Catalyst, Summa Health deal will turn on physician buy

hotspot

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Do digital therapeutics have a future in medicine?

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Readout Newsletter: The latest on Novavax, Merck, Bluebird

How generative AI ratchets up security threats for health systems

The lessons of Aduhelm, an Alzheimer's drug that was not to be

entertainment

explore

focus

leisure time